Market Cap 91.29M
Revenue (ttm) 0.00
Net Income (ttm) -23.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,302,700
Avg Vol 1,639,860
Day's Range N/A - N/A
Shares Out 89.50M
Stochastic %K 16%
Beta 1.75
Analysts Strong Sell
Price Target $3.50

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mi...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 481 2210
Address:
2500 Westchester Ave., Purchase, United States
Earlyinv
Earlyinv Jul. 15 at 12:14 PM
$CGTX Capt. Chesley 'Sully' Sullenberger reveals Alzheimer's diagnosis - ABC News https://abcnews.com/news/story/capt-sully-sullenberger-reveals-alzheimers-diagnosis/?id=134751717
0 · Reply
Beach_Bums
Beach_Bums Jul. 15 at 5:25 AM
0 · Reply
ForestFoxes
ForestFoxes Jul. 15 at 4:33 AM
An $ANVS truth @ReturnOfEsquire that's a 100% accurate. Maybe "900%" accurate 😂 if I were to quote Dr. Maccecchini. All the former CFOs wish for is to forget they were ever associated with Dr. Maccecchini and her sham of a company, Annovis Bio. I have no idea how or with what she will be using to lured fresh CFO replacement meat into her lair. Perhaps it was a typo ... or, perhaps a subconscious slip, but even former CFO #MarkGuerin of Annovis Bio has incorrectly associated himself with $AVXL (a company that he has never been a CFO at). See Image 1. That's from, "The Road Ahead: Perspectives from CFGI Philadelphia": https://www.cfgi.com/2026/05/26/the-road-ahead-perspectives-from-cfgi-philadelphia/ See Image 2. Image 3 speaks for itself, but as you've so accurately described, Jim, most members of this OTC-esque Stocktwits channel will explain this image with excuses such as all the five (5) former CFOs were not worth their salt, letting Dr. Maccecchini down, being failures, and/or the many negative things she no doubt spews to shareholders in private communications despite her legal counsel warning her and telling her to "Shut up". Yes, that's a quote from Dr. Maccecchini herself about what her legal counsel told her. But, alas this type of behavior is apparently something that Dr. Maccecchini is likely proud since she shares this so unabashedly. I'd let this go if it wasn't for the fact that Dr. Maccecchini is poaching families and patients to buy her stock. I wish she would stop, but I know she won't : ( See Image 4 ... which is abhorrent. P.S. You are correct that if Annovis Bio's molecule fails, it has nothing to do with big pharma. It also won't have anything to do with biomarkers, patients, and/or Clinical Research Organizations (CMO) that Dr. Maccecchini has publicly blames. She on the record for public stating that grandmothers faked Alzheimer's and I know she's screamed at representatives for what in my opinion are the failings of her own mismanagement and poorly designed drug trials and their protocols. Ugg. I'm going to try to let this go ... Tagging the following CNS companies as a warning to those shareholders in the same space to keep away from Annovis Bio: $SLS $CGTX $LLY
2 · Reply
SharkLips
SharkLips Jul. 14 at 7:57 PM
0 · Reply
Aimforsuccess
Aimforsuccess Jul. 14 at 2:28 PM
$CGTX Part of the game played by shorts with the help of market makers. Rob retail thru scare tactics in my opinion.
0 · Reply
goldenxb
goldenxb Jul. 14 at 1:46 PM
$CGTX shorts keep playing games; I keep buying
1 · Reply
TradeWarriorXXL
TradeWarriorXXL Jul. 13 at 8:38 PM
$CGTX Press Release link: https://ir.cogrx.com/press_releases/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-muscle-vision-summit/
0 · Reply
agarfield
agarfield Jul. 13 at 8:02 PM
$CGTX davenport has bumped their ownership to 4.2 mil shares https://fintel.io/so/us/cgtx/davenport-co-llc
0 · Reply
Aimforsuccess
Aimforsuccess Jul. 13 at 5:06 PM
$CGTX Always expect the shorts to promote false, negative information when trying to take it down.
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 13 at 4:54 PM
a price target of $36 and a dividend yield of 7%? these pfizer pharma bonds are hotter than those little blue pills they used to sell. i met the guy who led the marketing campaign. His name is Charlie, he is 84, and he is one of the "Mad Men" of pharma - he marketed Viagra 30 years ago at the peak of his career! Now he is retired, single, and a New York Giants fan. He is auctioning himself off for a charity soon at the Snow Ball - let's start the bidding at $85 eh ladies? you see, Charlie may be a widower... but he never needed those blue pills, and word at the nursing home is that he still DOESN'T! RIMSHOT! HEY YO! I'm working on my standup comedy routine. do you like this? buy $PFE $CGTX $TLSA and maybe a bit of $TNXP .. cyclobenzaprine is too old to be a standard of care! it makes you stupid long term!
2 · Reply
Latest News on CGTX
Cognition Therapeutics gets FDA feedback on zervimesine study

2026-06-24T11:40:14.000Z - 21 days ago

Cognition Therapeutics gets FDA feedback on zervimesine study


Cognition Therapeutics Transcript: AGM 2026

Jun 17, 2026, 9:00 AM EDT - 27 days ago

Cognition Therapeutics Transcript: AGM 2026


Cognition Therapeutics Slides: Investor presentation

Jun 4, 2026, 7:00 AM EDT - 5 weeks ago

Cognition Therapeutics Slides: Investor presentation


Cognition Therapeutics conducts zervimesine meeting with FDA

2026-05-21T11:48:47.000Z - 7 weeks ago

Cognition Therapeutics conducts zervimesine meeting with FDA


Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)

2026-05-07T23:09:07.000Z - 2 months ago

Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)


Cognition Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Cognition Therapeutics Earnings release: Q1 2026


Cognition Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Cognition Therapeutics Quarterly report: Q1 2026


Cognition Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Cognition Therapeutics Proxy statement: Proxy filing


Cognition Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Cognition Therapeutics Proxy statement: Proxy filing


Cognition Therapeutics CEO Issues Letter to Shareholders

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Cognition Therapeutics CEO Issues Letter to Shareholders


Cognition Therapeutics Earnings Call Transcript: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Cognition Therapeutics Earnings Call Transcript: Q4 2025


Cognition Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Cognition Therapeutics Earnings release: Q4 2025


Cognition Therapeutics Annual report: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Cognition Therapeutics Annual report: Q4 2025


Cognition Therapeutics Slides: Corporate presentation

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Cognition Therapeutics Slides: Corporate presentation


Cognition Therapeutics extends duration of EAP for zervimesine

2026-02-05T12:35:13.000Z - 5 months ago

Cognition Therapeutics extends duration of EAP for zervimesine


Cognition publishes Phase 2 results on Zervimesine

2026-01-06T12:41:42.000Z - 6 months ago

Cognition publishes Phase 2 results on Zervimesine


Cognition Therapeutics files $300M mixed securities shelf

2025-12-18T21:15:25.000Z - 7 months ago

Cognition Therapeutics files $300M mixed securities shelf


Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

2025-11-06T12:41:38.000Z - 8 months ago

Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)


Cognition Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:30 AM EST - 8 months ago

Cognition Therapeutics Quarterly report: Q3 2025


Cognition Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:30 AM EST - 8 months ago

Cognition Therapeutics Earnings release: Q3 2025


Cognition Therapeutics regains compliance with Nasdaq

2025-08-26T20:05:36.000Z - 11 months ago

Cognition Therapeutics regains compliance with Nasdaq


Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)

2025-08-07T20:10:27.000Z - 1 year ago

Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)


Cognition Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Cognition Therapeutics Earnings release: Q2 2025


Cognition Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Cognition Therapeutics Quarterly report: Q2 2025


Cognition Therapeutics Quarterly report: Q1 2025

May 7, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Quarterly report: Q1 2025


Cognition Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Earnings release: Q1 2025


Cognition Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Proxy statement: Proxy Filing


Cognition Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Proxy statement: Proxy Filing


Cognition Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Earnings Call Transcript: Q4 2024


Cognition Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Earnings release: Q4 2024


Cognition Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Annual report: Q4 2024


Cognition Therapeutics Transcript: Study Result

Dec 18, 2024, 8:00 AM EST - 1 year ago

Cognition Therapeutics Transcript: Study Result


Cognition Therapeutics Press release: Study Result

Dec 18, 2024, 8:00 AM EST - 1 year ago

Cognition Therapeutics Press release: Study Result


Cognition Therapeutics Transcript: Life Sciences Investor Forum

Nov 14, 2024, 11:00 AM EST - 1 year ago

Cognition Therapeutics Transcript: Life Sciences Investor Forum


Cognition Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Quarterly report: Q3 2024


Cognition Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Earnings release: Q3 2024


Earlyinv
Earlyinv Jul. 15 at 12:14 PM
$CGTX Capt. Chesley 'Sully' Sullenberger reveals Alzheimer's diagnosis - ABC News https://abcnews.com/news/story/capt-sully-sullenberger-reveals-alzheimers-diagnosis/?id=134751717
0 · Reply
Beach_Bums
Beach_Bums Jul. 15 at 5:25 AM
0 · Reply
ForestFoxes
ForestFoxes Jul. 15 at 4:33 AM
An $ANVS truth @ReturnOfEsquire that's a 100% accurate. Maybe "900%" accurate 😂 if I were to quote Dr. Maccecchini. All the former CFOs wish for is to forget they were ever associated with Dr. Maccecchini and her sham of a company, Annovis Bio. I have no idea how or with what she will be using to lured fresh CFO replacement meat into her lair. Perhaps it was a typo ... or, perhaps a subconscious slip, but even former CFO #MarkGuerin of Annovis Bio has incorrectly associated himself with $AVXL (a company that he has never been a CFO at). See Image 1. That's from, "The Road Ahead: Perspectives from CFGI Philadelphia": https://www.cfgi.com/2026/05/26/the-road-ahead-perspectives-from-cfgi-philadelphia/ See Image 2. Image 3 speaks for itself, but as you've so accurately described, Jim, most members of this OTC-esque Stocktwits channel will explain this image with excuses such as all the five (5) former CFOs were not worth their salt, letting Dr. Maccecchini down, being failures, and/or the many negative things she no doubt spews to shareholders in private communications despite her legal counsel warning her and telling her to "Shut up". Yes, that's a quote from Dr. Maccecchini herself about what her legal counsel told her. But, alas this type of behavior is apparently something that Dr. Maccecchini is likely proud since she shares this so unabashedly. I'd let this go if it wasn't for the fact that Dr. Maccecchini is poaching families and patients to buy her stock. I wish she would stop, but I know she won't : ( See Image 4 ... which is abhorrent. P.S. You are correct that if Annovis Bio's molecule fails, it has nothing to do with big pharma. It also won't have anything to do with biomarkers, patients, and/or Clinical Research Organizations (CMO) that Dr. Maccecchini has publicly blames. She on the record for public stating that grandmothers faked Alzheimer's and I know she's screamed at representatives for what in my opinion are the failings of her own mismanagement and poorly designed drug trials and their protocols. Ugg. I'm going to try to let this go ... Tagging the following CNS companies as a warning to those shareholders in the same space to keep away from Annovis Bio: $SLS $CGTX $LLY
2 · Reply
SharkLips
SharkLips Jul. 14 at 7:57 PM
0 · Reply
Aimforsuccess
Aimforsuccess Jul. 14 at 2:28 PM
$CGTX Part of the game played by shorts with the help of market makers. Rob retail thru scare tactics in my opinion.
0 · Reply
goldenxb
goldenxb Jul. 14 at 1:46 PM
$CGTX shorts keep playing games; I keep buying
1 · Reply
TradeWarriorXXL
TradeWarriorXXL Jul. 13 at 8:38 PM
$CGTX Press Release link: https://ir.cogrx.com/press_releases/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-muscle-vision-summit/
0 · Reply
agarfield
agarfield Jul. 13 at 8:02 PM
$CGTX davenport has bumped their ownership to 4.2 mil shares https://fintel.io/so/us/cgtx/davenport-co-llc
0 · Reply
Aimforsuccess
Aimforsuccess Jul. 13 at 5:06 PM
$CGTX Always expect the shorts to promote false, negative information when trying to take it down.
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 13 at 4:54 PM
a price target of $36 and a dividend yield of 7%? these pfizer pharma bonds are hotter than those little blue pills they used to sell. i met the guy who led the marketing campaign. His name is Charlie, he is 84, and he is one of the "Mad Men" of pharma - he marketed Viagra 30 years ago at the peak of his career! Now he is retired, single, and a New York Giants fan. He is auctioning himself off for a charity soon at the Snow Ball - let's start the bidding at $85 eh ladies? you see, Charlie may be a widower... but he never needed those blue pills, and word at the nursing home is that he still DOESN'T! RIMSHOT! HEY YO! I'm working on my standup comedy routine. do you like this? buy $PFE $CGTX $TLSA and maybe a bit of $TNXP .. cyclobenzaprine is too old to be a standard of care! it makes you stupid long term!
2 · Reply
greenacorn
greenacorn Jul. 13 at 4:48 PM
0 · Reply
Beach_Bums
Beach_Bums Jul. 13 at 4:31 PM
$CGTX taken from ChatGPT for those asking about CGTX being at the AAIC
0 · Reply
Ajbatt
Ajbatt Jul. 13 at 4:22 PM
$CGTX are they presenting at the AAIC ? Seems like a very basic question, apparently not The IR dept is seriously lacking big time absolutely amazing!!!
0 · Reply
mcclayjd40
mcclayjd40 Jul. 13 at 3:16 PM
$CGTX Getting conflicting info about them presenting at AAIC. Sent IR an email to confirm but never got back to me. Unless there’s something happening behind the scenes this will drift down significantly.
3 · Reply
Aimforsuccess
Aimforsuccess Jul. 13 at 2:50 PM
$CGTX Shorts and market makers hitting it hard thus morning? Disparate to get in?
0 · Reply
skipperballs
skipperballs Jul. 13 at 1:45 PM
$CGTX this down on hardly any volume. MM bs most likely. I predice we close today back around 110.
1 · Reply
Aimforsuccess
Aimforsuccess Jul. 12 at 3:13 AM
$CGTX Why should it take over a year to start the trial? The company has already run very similar trials. Yes, I know funding may be somewhat of an issue, but may part of the reason be that the time extension gives potential acquirers plenty of time to complete their due diligence without CGTX having already committed to certain aspects of the trial protocol?
1 · Reply
bernoneill
bernoneill Jul. 11 at 10:45 AM
$CGTX I like that it is holding. I thought they may be diluting a small bit, but share count is still 89.5M (Yahoo) - maybe that takes a while to update? Good luck all longs.
1 · Reply
endrow
endrow Jul. 10 at 3:09 PM
$ACOG $CGTX $AVXL $LLY Crazy that Alpha Cognition is still under the radar. They are selling their FDA approved oral drug for a year now, have great revenue growth AND their recent study shows that Zunveyl actually IMPROVES(!!) most of the patients cognitive conditions, which is unheard of for an Alzheimer's drug. They also just got an outperform rating and a $20 price target. In my opinion this company should be worth billions already and will be worth billions in a year or two, when the market finally discovers it. https://www.investing.com/news/analyst-ratings/raymond-james-initiates-alpha-cognition-stock-coverage-with-outperform-rating-93CH-4785839
1 · Reply
fda_tracker
fda_tracker Jul. 9 at 6:52 PM
$CGTX Phase 2 trial w/est Jul completion date NCT07523048: https://www.clinicaltrials.gov/study/NCT07523048 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
bernoneill
bernoneill Jul. 9 at 6:26 PM
$CGTX How to you all see ANVS buntanetap as competition to CT1812? I am long CGTX, but thought there were some reaction issues with buntanetap. Reviewing again, I don't see any issues now and they have P3 fully enrolled now - huge, 850 patients. Any thoughts? Thx.
2 · Reply
nonameleavemealone
nonameleavemealone Jul. 9 at 4:48 PM
$CGTX Realistic price target given a decent catalyst? within 6m.
1 · Reply